LAS VEGAS, NV / ACCESSWIRE / June 27, 2016 / Propanc Health Group Corporation (PPCH) has just announced significant progress of development activities ahead of the FirstInMan studies for their PRP treatment.
FirstInMan studies are exactly what they sound like, the first studies on human subjects, in some circles it is referred to as Phase 0.
Why is this big?
Because this means PPCH is close to becoming a clinical stage biotechnology company. This is a major milestone on the horizon. There are several markers in between which should make for exciting announcement and could help bring this oversold company back to its 2015 highs.
“Over the last six months, Propanc’s development team has worked extremely hard to progress PRP to a stage where a constructive discussion could be held with the MHRA to define our development pathway,” said James Nathanielsz, Propanc’s Chief Executive Officer. “I am pleased to say we had a successful meeting and are working hard to complete the activities necessary to support a clinical trial application. So far, it appears we are on track to complete this goal early next year and I am delighted with the level of commitment and effort shown by our Development team. As I mentioned previously, we are presently transforming into a clinical stage biopharmaceutical company and I expect more exciting developments to unfold this year as we progress towards first in man studies for PRP.”
Point is, Propanc is sitting at a bottom, and has a litany of positive announcements ahead potentially. Now would be a great time to buy your tickets for what should be a fun ride up heading into next year’s trials.
Here’s a couple other comeback stocks making waves in the market.
Achaogen, Inc. (AKAO) was recently upgraded to outperform by Wedbush and their analysis looks to be proven right so far.
Mast Therapeutics (MSTX) has recovered this week despite less than stellar Q1 numbers.
ProNAi Therapeutics, Inc. (DNAI) was perhaps the biggest loser from the ASCO meeting. The company announced interim results from the Wolverine Phase 2 trial of PNT2258 for the treatment of relapsed or refractory diffuse large Bcell lymphoma. Results from this midstage trial were disappointing and modest efficacy was seen, at best. However, the clinical stage company has worked backup since their struggles.
Immunomedics, Inc. (IMMU) is undergoing a class action lawsuit.
Otonomy, Inc. (OTIC) recently initiated patient enrollment for their Phase 3 Clinical Trial of OTIPRIOTM in patients with Acute Otitis Externa.
Of all of these comeback candidates, PPCH is our favorite.
FirstInMan studies are exactly what they sound like, the first studies on human subjects, in some circles it is referred to as Phase 0.
Why is this big?
Because this means PPCH is close to becoming a clinical stage biotechnology company. This is a major milestone on the horizon. There are several markers in between which should make for exciting announcement and could help bring this oversold company back to its 2015 highs.
“Over the last six months, Propanc’s development team has worked extremely hard to progress PRP to a stage where a constructive discussion could be held with the MHRA to define our development pathway,” said James Nathanielsz, Propanc’s Chief Executive Officer. “I am pleased to say we had a successful meeting and are working hard to complete the activities necessary to support a clinical trial application. So far, it appears we are on track to complete this goal early next year and I am delighted with the level of commitment and effort shown by our Development team. As I mentioned previously, we are presently transforming into a clinical stage biopharmaceutical company and I expect more exciting developments to unfold this year as we progress towards first in man studies for PRP.”
Point is, Propanc is sitting at a bottom, and has a litany of positive announcements ahead potentially. Now would be a great time to buy your tickets for what should be a fun ride up heading into next year’s trials.
Here’s a couple other comeback stocks making waves in the market.
Achaogen, Inc. (AKAO) was recently upgraded to outperform by Wedbush and their analysis looks to be proven right so far.
Mast Therapeutics (MSTX) has recovered this week despite less than stellar Q1 numbers.
ProNAi Therapeutics, Inc. (DNAI) was perhaps the biggest loser from the ASCO meeting. The company announced interim results from the Wolverine Phase 2 trial of PNT2258 for the treatment of relapsed or refractory diffuse large Bcell lymphoma. Results from this midstage trial were disappointing and modest efficacy was seen, at best. However, the clinical stage company has worked backup since their struggles.
Immunomedics, Inc. (IMMU) is undergoing a class action lawsuit.
Otonomy, Inc. (OTIC) recently initiated patient enrollment for their Phase 3 Clinical Trial of OTIPRIOTM in patients with Acute Otitis Externa.
Of all of these comeback candidates, PPCH is our favorite.
